Literature DB >> 21688187

Resveratrol in cardiovascular disease: what is known from current research?

Hong Wang1, Yue-Jin Yang, Hai-Yan Qian, Qian Zhang, Hui Xu, Jian-Jun Li.   

Abstract

Resveratrol is a well-known antioxidant that exists in grape skin/seed, red wine, and the root of Polygonum cuspidatum, a traditional Chinese and Japanese medicinal material. Studies have found that resveratrol has many interesting properties, including anti-carcinogenic properties, anti-microbial and antiviral effects, the ability to reverse dyslipidemia and obesity, the ability to attenuate hyperglycemia and hyperinsulinemia, and the ability to protect endothelial function. Heart failure is the final consequence of the majority of cardiovascular diseases, and resveratrol has been shown to directly attenuate heart contraction. The cardiovascular protective capacities of resveratrol are associated with multiple molecular targets and may lead to the development of novel therapeutic strategies for atherosclerosis, ischemia/reperfusion, metabolic syndrome, and heart failure. This article will mainly review recently published basic researches about the protective cardiovascular effects of resveratrol because these results may lead to the development of new clinical therapeutics in patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21688187     DOI: 10.1007/s10741-011-9260-4

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  136 in total

1.  Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.

Authors:  Toshihiko Ishimitsu; Atsushi Numabe; Toshihide Masuda; Tomoyuki Akabane; Atsushi Okamura; Junichi Minami; Hiroaki Matsuoka
Journal:  Hypertens Res       Date:  2009-08-21       Impact factor: 3.872

2.  Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension.

Authors:  Hiroyoshi Ono; Shinya Minatoguchi; Kazuhiro Watanabe; Yoshihisa Yamada; Takahisa Mizukusa; Hironobu Kawasaki; Hidemi Takahashi; Takashi Uno; Tatsuo Tsukamoto; Kunihiko Hiei; Hisayoshi Fujiwara
Journal:  Hypertens Res       Date:  2008-02       Impact factor: 3.872

3.  Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model.

Authors:  J Zou; Y Huang; K Cao; G Yang; H Yin; J Len; T C Hsieh; J M Wu
Journal:  Life Sci       Date:  2000-12-01       Impact factor: 5.037

4.  Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1.

Authors:  Joseph T Rodgers; Carlos Lerin; Wilhelm Haas; Steven P Gygi; Bruce M Spiegelman; Pere Puigserver
Journal:  Nature       Date:  2005-03-03       Impact factor: 49.962

5.  Apocynin protects against global cerebral ischemia-reperfusion-induced oxidative stress and injury in the gerbil hippocampus.

Authors:  Qun Wang; Kenneth D Tompkins; Agnes Simonyi; Ronald J Korthuis; Albert Y Sun; Grace Y Sun
Journal:  Brain Res       Date:  2006-05-02       Impact factor: 3.252

6.  Effects of resveratrol (trans-3,5,4'-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction.

Authors:  Brett Burstein; Ange Maguy; Robert Clément; Hugues Gosselin; Francine Poulin; Nathalie Ethier; Jean-Claude Tardif; Terence E Hébert; Angelino Calderone; Stanley Nattel
Journal:  J Pharmacol Exp Ther       Date:  2007-09-17       Impact factor: 4.030

7.  Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway.

Authors:  Narasimman Gurusamy; Istvan Lekli; Subhendu Mukherjee; Diptarka Ray; Md Kaimul Ahsan; Mihaela Gherghiceanu; Lawrence M Popescu; Dipak K Das
Journal:  Cardiovasc Res       Date:  2009-12-03       Impact factor: 10.787

8.  Curcumin synergizes with resveratrol to inhibit colon cancer.

Authors:  Adhip P N Majumdar; Sanjeev Banerjee; Jyoti Nautiyal; Bhaumik B Patel; Vaishali Patel; Jianhua Du; Yingjie Yu; Althea A Elliott; Edi Levi; Fazlul H Sarkar
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

9.  Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis.

Authors:  Isabelle Mader; Martin Wabitsch; Klaus-Michael Debatin; Pamela Fischer-Posovszky; Simone Fulda
Journal:  FASEB J       Date:  2010-01-22       Impact factor: 5.191

Review 10.  Autophagy, redox signaling, and ventricular remodeling.

Authors:  Narasimman Gurusamy; Dipak K Das
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

View more
  25 in total

1.  Anti-oxidized low-density lipoprotein antibodies in chronic heart failure.

Authors:  Gideon Charach; Alexander Rabinovich; Ori Argov; Moshe Weintraub; Lior Charach; Oded Ayzenberg; Jacob George
Journal:  World J Cardiol       Date:  2012-11-26

2.  Alcohol consumption and risk of death in male physicians with heart failure.

Authors:  Andrew B Petrone; J Michael Gaziano; Luc Djoussé
Journal:  Am J Cardiol       Date:  2014-07-18       Impact factor: 2.778

3.  Supplementing exercise: translational considerations for nutraceutical and lifestyle interventions.

Authors:  Jessica R Santos-Parker; Rachelle E Kaplon
Journal:  J Physiol       Date:  2014-02-01       Impact factor: 5.182

Review 4.  Resveratrol supplementation: Where are we now and where should we go?

Authors:  Marta G Novelle; Devin Wahl; Carlos Diéguez; Michel Bernier; Rafael de Cabo
Journal:  Ageing Res Rev       Date:  2015-01-24       Impact factor: 10.895

Review 5.  Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies.

Authors:  Olesya Ilkun; Sihem Boudina
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

6.  Endothelium-dependent and-independent relaxation induced by resveratrol in rat superior mesenteric arteries.

Authors:  Yulong Chen; Cangbao Xu; Yahui Wei; Yaping Zhang; Ailan Cao
Journal:  Exp Ther Med       Date:  2016-08-22       Impact factor: 2.447

Review 7.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 8.  Mitochondria as a therapeutic target in heart failure.

Authors:  Marina Bayeva; Mihai Gheorghiade; Hossein Ardehali
Journal:  J Am Coll Cardiol       Date:  2012-12-05       Impact factor: 24.094

Review 9.  Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases.

Authors:  Erin G Rosenbaugh; Krupa K Savalia; Devika S Manickam; Matthew C Zimmerman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-03       Impact factor: 3.619

10.  Cytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive rats.

Authors:  Brett L Jennings; David E Montanez; Michael E May; Anne M Estes; Xiao R Fang; Fariborz A Yaghini; Alie Kanu; Kafait U Malik
Journal:  Cardiovasc Drugs Ther       Date:  2014-04       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.